Molecular genetic tests in the prediction of the prognosis of breast cancer

F. R. Stoddard, A. Szász, B. Szekely, A. Tőkés, J. Kulka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Summary: Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalMemo - Magazine of European Medical Oncology
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Molecular Biology
Breast Neoplasms
Molecular Pathology
Hormones
Pathology
Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • diagnostics
  • prediction
  • prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Molecular genetic tests in the prediction of the prognosis of breast cancer. / Stoddard, F. R.; Szász, A.; Szekely, B.; Tőkés, A.; Kulka, J.

In: Memo - Magazine of European Medical Oncology, Vol. 4, No. 3, 09.2011, p. 158-162.

Research output: Contribution to journalArticle

@article{41e39e29408f4545a52212dfbdf39ab5,
title = "Molecular genetic tests in the prediction of the prognosis of breast cancer",
abstract = "Summary: Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation.",
keywords = "Breast cancer, diagnostics, prediction, prognosis",
author = "Stoddard, {F. R.} and A. Sz{\'a}sz and B. Szekely and A. Tők{\'e}s and J. Kulka",
year = "2011",
month = "9",
doi = "10.1007/s12254-011-0285-0",
language = "English",
volume = "4",
pages = "158--162",
journal = "Memo - Magazine of European Medical Oncology",
issn = "1865-5041",
publisher = "Springer Wien",
number = "3",

}

TY - JOUR

T1 - Molecular genetic tests in the prediction of the prognosis of breast cancer

AU - Stoddard, F. R.

AU - Szász, A.

AU - Szekely, B.

AU - Tőkés, A.

AU - Kulka, J.

PY - 2011/9

Y1 - 2011/9

N2 - Summary: Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation.

AB - Summary: Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation.

KW - Breast cancer

KW - diagnostics

KW - prediction

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=82055172856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82055172856&partnerID=8YFLogxK

U2 - 10.1007/s12254-011-0285-0

DO - 10.1007/s12254-011-0285-0

M3 - Article

AN - SCOPUS:82055172856

VL - 4

SP - 158

EP - 162

JO - Memo - Magazine of European Medical Oncology

JF - Memo - Magazine of European Medical Oncology

SN - 1865-5041

IS - 3

ER -